Business
Ligand to Host Virtual Investor Day on October 20th
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday,
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be:\n\n\nJohn Higgins, Chief Executive Officer\n\n\nMatt Foehr, President and Chief Operation Officer\n\n\nMatt Korenberg, Chief Financial Officer\n\n\nVince Antle, PhD, SVP Technical Operations and Quality Assurance\n\n\nPatrick Lucy, SVP and Chief Business Officer, Protein Expression Business\n\n\nMatthew R. Davis, PharmD, Infectious Disease Pharmacist at the University of California Los Angeles – Ronald Reagan Medical Center\n\n\nLigand’s company presentations will include the following topics:\n\n\nIntroduction of 2021 financial guidance and overview of financial outlook for the next three years\n\n\nPresentation of key assets and value drivers for the recently closed Pfenex acquisition\n\n\nCaptisol’s role in formulations of remdesivir and ramp-up of production\n\n\nOutlook for Captisol given growth drivers from existing partners, potential new products and potential demand from the remdesivir COVID-19 treatment consortium\n\n\nSummary of major pivotal clinical trial data and late-stage regulatory events expected by partners over the next 15 months\n\n\nOutlook for the OmniAb® antibody business, including late-stage clinical and regulatory events\n\n\nOverview of newly acquired PF810 as well as Captisol-enabled internal R&D programs\n\n\nReview of capital deployment strategy\n\n\nIn addition, Dr. Matthew Davis, an infectious diseases medical expert and thought leader, will review current COVID-19 treatment guidelines, the COVID-19 antiviral treatment landscape, and mechanistic and structural considerations of medicines targeting coronaviruses.\n\nTo listen to the webcast and view the presentation slides, please visit https://investor.ligand.com/ir-calendar. To participate in the Q&A portion of the event, please dial (833) 325-0071 within the U.S. or (720) 405-1612 outside the U.S. and use Conference ID 4279228. Questions can also be submitted via email during the event to [email protected].\n\nThe webcast will be archived on the Ligand website for 90 days following the event.\n\nAbout Matthew R. Davis, PharmD\n\nDr. Davis obtained his Doctorate of Pharmacy from the Universit...